Small Molecule Regulators Targeting NAD+ Biosynthetic Enzymes

被引:3
作者
Curry, Alyson [1 ]
White, Dawanna [1 ]
Cen, Yana [1 ,2 ]
机构
[1] Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23219 USA
[2] Virginia Commonwealth Univ, Inst Struct Biol Drug Discovery & Dev, Richmond, VA 23219 USA
关键词
Nicotinamide adenine dinucleotide (NAD(+)); metabolic pathways; electrons; redox reactions; enzymatic transformations; therapeutic potentials; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE NAMPT; PERMEABILITY TRANSITION PORE; NEURONAL CELL-DEATH; INDOLEAMINE 2,3-DIOXYGENASE; CRYSTAL-STRUCTURE; ACID PHOSPHORIBOSYLTRANSFERASE; KYNURENINE; 3-MONOOXYGENASE; ADENINE-DINUCLEOTIDE; POTENT INHIBITOR; SALVAGE PATHWAY;
D O I
10.2174/0929867328666210531144629
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nicotinamide adenine dinucleotide (NAD(+)) is a key player in many metabolic pathways as an activated carrier of electrons. In addition to being the cofactor for redox reactions, NAD(+) also serves as the substrate for various enzymatic transformations such as adenylation and ADP-ribosylation. Maintaining cellular NAD(+) homeostasis has been suggested as an effective anti-aging strategy. Given the importance of NAD(+) in regulating a broad spectrum of cellular events, small molecules targeting NAD+ metabolism have been pursued as therapeutic interventions for the treatment of mitochondrial disorders and age-related diseases. In this article, small molecule regulators of NAD(+) biosynthetic enzymes will be reviewed. The focus will be given to the discovery and development of these molecules, the mechanism of action as well as their therapeutic potentials.
引用
收藏
页码:1718 / 1738
页数:21
相关论文
共 150 条
  • [1] Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth
    Abu Aboud, Omran
    Chen, Ching-Hsien
    Senapedis, William
    Baloglu, Erkan
    Argueta, Christian
    Weiss, Robert H.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2016, 15 (09) : 2119 - 2129
  • [2] NMNATs, evolutionarily conserved neuronal maintenance factors
    Ali, Yousuf O.
    Li-Kroeger, David
    Bellen, Hugo J.
    Zhai, R. Grace
    Lu, Hui-Chen
    [J]. TRENDS IN NEUROSCIENCES, 2013, 36 (11) : 632 - 640
  • [3] Structural basis of kynurenine 3-monooxygenase inhibition
    Amaral, Marta
    Levy, Colin
    Heyes, Derren J.
    Lafite, Pierre
    Outeiro, Tiago F.
    Giorgini, Flaviano
    Leys, David
    Scrutton, Nigel S.
    [J]. NATURE, 2013, 496 (7445) : 382 - +
  • [4] Manipulation of a nuclear NAD+ salvage pathway delays aging without altering steady-state NAD+ levels
    Anderson, RM
    Bitterman, KJ
    Wood, JG
    Medvedik, O
    Cohen, H
    Lin, SS
    Manchester, JK
    Gordon, JI
    Sinclair, DA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (21) : 18881 - 18890
  • [5] Transcriptional activation of indoleamine dioxygenase by interleukin 1 and tumor necrosis factor α in interferon-treated epithelial cells
    Babcock, TA
    Carlin, JM
    [J]. CYTOKINE, 2000, 12 (06) : 588 - 594
  • [6] The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease
    Beaumont, Vahri
    Mrzljak, Ladislav
    Dijkman, Ulrike
    Freije, Robert
    Heins, Mariette
    Rassoulpour, Arash
    Tombaugh, Geoffrey
    Gelman, Simon
    Bradaia, Amyaouch
    Steidl, Esther
    Gleyzes, Melanie
    Heikkinen, Taneli
    Lehtimaki, Kimmo
    Puolivali, Jukka
    Kontkanen, Outi
    Javier, Robyn M.
    Neagoe, Ioana
    Deisemann, Heike
    Winkler, Dirk
    Ebneth, Andreas
    Khetarpal, Vinod
    Toledo-Sherman, Leticia
    Dominguez, Celia
    Park, Larry C.
    Munoz-Sanjuan, Ignacio
    [J]. EXPERIMENTAL NEUROLOGY, 2016, 282 : 99 - 118
  • [7] Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777
    Beauparlant, Pierre
    Bedard, Dominique
    Bernier, Cynthia
    Chan, Helen
    Gilbert, Karine
    Goulet, Daniel
    Gratton, Michel-Olivier
    Lavoie, Manon
    Roulston, Anne
    Turcotte, Emilie
    Watson, Mark
    [J]. ANTI-CANCER DRUGS, 2009, 20 (05) : 346 - 354
  • [8] NAD+ metabolism in health and disease
    Belenky, Peter
    Bogan, Katrina L.
    Brenner, Charles
    [J]. TRENDS IN BIOCHEMICAL SCIENCES, 2007, 32 (01) : 12 - 19
  • [9] Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+
    Belenky, Peter
    Racette, Frances G.
    Bogan, Katrina L.
    McClure, Julie M.
    Smith, Jeffrey S.
    Brenner, Charles
    [J]. CELL, 2007, 129 (03) : 473 - 484
  • [10] Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms
    Berger, F
    Lau, C
    Dahlmann, M
    Ziegler, M
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (43) : 36334 - 36341